Robert Dreicer, M.D.
| Appointed: |
1999 |
| Gender: |
Male |
| Languages: |
English |
Solid Tumor Oncology
Taussig Cancer Institute
Urology
Biographical Sketch
Robert Dreicer, MD, FACP, is Chairman of the Department of Solid Tumor Oncology at Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Dr. Dreicer is board-certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his B.S. degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his medical degree from the University of Texas Medical School at Houston.
He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison, Wisconsin. He joined the Division of Hematology/Oncology at the University of Iowa in 1989 and upon his departure He was a tenured Associate Professor of Medicine and Associate Division Director of Hematology/Oncology. Dr. Dreicer was appointed as a Staff Physician in Hematology/Oncology with a secondary appointment in the Urologic Institute.
He was appointed Director of the Genitourinary Medical Oncology program and Associate Director of the Experimental Therapeutics Program in 2000 and Chairman of the Department of Solid Tumor Oncology in January of 2006 . Dr. Dreicer has published widely in genitourinary oncology, and is the principle investigator of a large number of ongoing studies in genitourinary neoplasms. He is the Chair of the Bladder Subcommittee of the Eastern Cooperative Oncology Group and a Fellow of the American College of Physicians.
He was Chair of the Steering Committee for ASCO's 2008 GU Oncology Meeting. He is, an Associate Editor of Urology, and a member of the editorial boards of the Journal of Clinical Oncology, the New England Journal of Medicine's Journal Watch Hematology/Oncology and The Journal Of Supportive Oncology. He is a member of the scientific advisory board of Transgene.
Professional Highlights
- Associate Editor, Urology
- Editorial Board, Journal of Clinical Oncology
- Editorial Board, Journal of Supportive Oncology
- Associate Editor, New England Journal of Medicine, Journal Watch Hematology/Oncology
Education & Fellowships
| Medical School: | University of Texas, Houston, Houston, TX |
|
| Internship: | Indiana University Medical Center, Internal Medicine, Indianapolis, IN |
| Residency: | Indiana University Medical Center, Internal Medicine, Indianapolis, IN |
| Fellowship: | University of Wisconsin Hospital and Clinic, Medical Oncology, Madison, WI |
| Other Education: | (Graduate) University of Texas, Houston, Houston, TX |
| Other Education: | (Undergraduate) Colorado State University, Fort Collins, CO |
Additional Training
- Master of Science, University of Texas Graduate School of Biomedical Sciences-Houston
Certifications
Medical Oncology
Internal Medicine
Specialty Interests
Experimental therapeutics, urologic oncology, Experimental Therapeutics.
Awards & Honors
- Fellow of the American College of Physicians
- America's Top Doctors For Cancer 2005, 2006, 2007, 2008, 2009 (Castle Connolly Ltd. Peer Nomination)
Professional Memberships
- American Society of Clinical Oncology
- Society of Urologic Oncology
- American Urologic Association
- American College of Physicians
Specializes in Diseases and Conditions
Specializes in Services
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 7/31/2008, Dr. Dreicer has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our
Integrity in Innovation page.
Consulting. Dr. Dreicer receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
( † Disclaimer: This search is powered by PubMed, a service of the U.S.
National Library of Medicine. PubMed is a third-party website with no
affiliation with Cleveland Clinic.)
